東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Interleukin 12 = antitumor activity ...

Lasek, Witold.

FindBook

Google Book

Amazon

博客來

Interleukin 12 = antitumor activity and immunotherapeutic potential in oncology /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Interleukin 12/ by Witold Lasek, Radoslaw Zagozdzon.
其他題名:	antitumor activity and immunotherapeutic potential in oncology /
作者:	Lasek, Witold.
其他作者:	Zagozdzon, Radoslaw.
出版者:	Cham :Springer International Publishing : : 2016.,
面頁冊數:	vii, 75 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
標題:	Interleukin-12. -
電子資源:	http://dx.doi.org/10.1007/978-3-319-46906-5
ISBN:	9783319469065$q(electronic bk.)

Interleukin 12 = antitumor activity and immunotherapeutic potential in oncology /
Lasek, Witold.

Interleukin 12antitumor activity and immunotherapeutic potential in oncology /[electronic resource] :by Witold Lasek, Radoslaw Zagozdzon. - Cham :Springer International Publishing :2016. - vii, 75 p. :ill., digital ;24 cm. - SpringerBriefs in immunology,2194-2773. - SpringerBriefs in immunology..

This book discusses the immunotherapeutic potential of Interleukin 12 in the context of clinical oncology, as well as antitumor effects confirmed in preclinical studies and clinical trials in cancer immunotherapy. Due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities, Interleukin 12 (IL-12) has been regarded as a promising candidate for tumor immunotherapy. However, despite the encouraging results in animal models, only very modest antitumor effects have been confirmed in early clinical trials. Recently, several clinical studies have been initiated in which IL-12 was applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid, and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies)

ISBN: 9783319469065$q(electronic bk.)

Standard No.: 10.1007/978-3-319-46906-5doiSubjects--Topical Terms:

3135874
Interleukin-12.

LC Class. No.: QR185.8.I56

Dewey Class. No.: 616.079

Interleukin 12 = antitumor activity and immunotherapeutic potential in oncology /
LDR:01853nmm a2200313 a 4500 001 2052484
003 DE-He213
005 20160923120258.0
006 m d
007 cr nn 008maaau
008 170421s2016 gw s 0 eng d
020 $a 9783319469065$q(electronic bk.)
020 $a 9783319469058$q(paper)
024 7 $a 10.1007/978-3-319-46906-5 $2 doi
035 $a 978-3-319-46906-5
040 $a GP $c GP
041 0 $a eng
050 4 $a QR185.8.I56
072 7 $a MJCM $2 bicssc
072 7 $a MED044000 $2 bisacsh
082 0 4 $a 616.079 $2 23
090 $a QR185.8.I56 $b L343 2016
100 1 $a Lasek, Witold. $3 3135872
245 1 0 $a Interleukin 12 $h [electronic resource] : $b antitumor activity and immunotherapeutic potential in oncology / $c by Witold Lasek, Radoslaw Zagozdzon.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2016.
300 $a vii, 75 p. : $b ill., digital ; $c 24 cm.
490 1 $a SpringerBriefs in immunology, $x 2194-2773
520 $a This book discusses the immunotherapeutic potential of Interleukin 12 in the context of clinical oncology, as well as antitumor effects confirmed in preclinical studies and clinical trials in cancer immunotherapy. Due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities, Interleukin 12 (IL-12) has been regarded as a promising candidate for tumor immunotherapy. However, despite the encouraging results in animal models, only very modest antitumor effects have been confirmed in early clinical trials. Recently, several clinical studies have been initiated in which IL-12 was applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid, and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies)
650 0 $a Interleukin-12. $3 3135874
650 1 4 $a Biomedicine. $3 890831
650 2 4 $a Immunology. $3 611031
650 2 4 $a Cancer Research. $3 891172
650 2 4 $a Cytokines and Growth Factors. $3 1084957
650 2 4 $a Oncology. $3 751006
650 2 4 $a Cell Biology. $3 892383
700 1 $a Zagozdzon, Radoslaw. $3 3135873
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a SpringerBriefs in immunology. $3 2133251
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-46906-5
950 $a Biomedical and Life Sciences (Springer-11642)